7,080 Shares in FibroGen Inc (FGEN) Purchased by Virtu Financial LLC
Virtu Financial LLC purchased a new stake in FibroGen Inc (NASDAQ:FGEN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,080 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.
Other institutional investors also recently modified their holdings of the company. Squarepoint Ops LLC bought a new position in FibroGen during the 4th quarter valued at about $2,391,000. Two Sigma Investments LP bought a new position in FibroGen during the 4th quarter valued at about $1,095,000. Norges Bank bought a new position in FibroGen during the 4th quarter valued at about $32,604,000. Vanguard Group Inc. lifted its holdings in FibroGen by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after purchasing an additional 125,186 shares during the last quarter. Finally, NJ State Employees Deferred Compensation Plan bought a new position in FibroGen during the 4th quarter valued at about $231,000. 66.58% of the stock is owned by hedge funds and other institutional investors.
FGEN opened at $46.83 on Tuesday. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -45.47 and a beta of 1.72. FibroGen Inc has a 1-year low of $37.27 and a 1-year high of $68.55.
Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a report on Tuesday, January 8th. Piper Jaffray Companies assumed coverage on shares of FibroGen in a report on Friday, April 12th. They set a “neutral” rating and a $65.00 price target for the company. BidaskClub downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a report on Friday, March 29th. Finally, ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. FibroGen presently has a consensus rating of “Buy” and an average price target of $71.17.
In other FibroGen news, CEO Thomas B. Neff sold 48,180 shares of the firm’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $56.47, for a total value of $2,720,724.60. Following the completion of the sale, the chief executive officer now owns 2,680,346 shares in the company, valued at approximately $151,359,138.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas B. Neff sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $52.00, for a total transaction of $3,120,000.00. Following the completion of the sale, the chief executive officer now owns 2,624,016 shares of the company’s stock, valued at approximately $136,448,832. The disclosure for this sale can be found here. Insiders sold a total of 328,721 shares of company stock valued at $17,983,268 in the last 90 days. Corporate insiders own 8.96% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.